Tonix Pharmaceuticals Holding Corp. TNXP R2K

Healthcare · Biotechnology · United States

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Market & Price

Market Cap

$196.55M

Current Price

$12.33

High / Low (52W)

$61.57 / $12.03

Beta

1.69

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$19.17

Price to Book

0.64

P/S

11.20

EV/EBITDA

-0.08

Dividend Yield

Profitability & Returns

ROCE

-50.31%

ROE

-72.33%

ROA

-41.92%

Profit Margin

0.00%

Op Margin

EPS (Latest Qtr)

$-2.93

EPS (TTM)

$-14.66

Balance Sheet & Liquidity

Debt/Equity

0.57

Quick Ratio

6.57

Current Ratio

6.99

Debt

$1.29M

Total Assets

$277.17M

Current Assets

$228.88M

Working Capital

$198.04M

Ownership

Promoter Holding

0.13%

Chg in Prom Hold

FII / Inst Holding

41.42%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$12.37M

Total Revenue (TTM)

$17.56M

EBITDA

$-149.20M

Free Cash Flow

$-76.73M

Operating Cash Flow

$-125.58M

Shares Outstanding

15.94M

Gross Margin

58.56%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-4.17%

Revenue (YoY)

183.20%

Earnings (YoY)

PROS

No notable strengths flagged.

CONS

Earnings shrank at -4.2% CAGR over 5 years.
Trading 80.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TNXP Tonix Pharmaceuticals Holding Corp. R2K	12.33	-	$196.55M	-	-50.31%	-72.33%	-	-4.17%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.99M	2.48M	2.21M	-	-	2.43M	2.00M	3.29M	5.39M	6.88M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	943.00K	3.27M	1.37M	1.06M	1.58M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.49M	-1.27M	1.92M	4.33M	5.30M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.62M	25.99M	34.01M	52.55M	46.84M
Operating Income	-6.05M	-7.43M	-9.00M	-9.70M	-11.78M	-13.28M	-13.40M	-14.01M	-9.84M	-7.61M	-5.09M	-4.82M	-5.83M	-6.99M	-6.14M	-5.54M	-6.30M	-5.91M	-7.89M	-7.30M	-14.19M	-12.00M	-20.74M	-23.56M	-18.54M	-26.44M	-23.34M	-29.59M	-33.90M	-29.00M	-28.15M	-21.35M	-77.32M	-	-	-15.13M	-27.26M	-32.09M	-48.22M	-41.54M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14.64M	-26.78M	-31.55M	-46.42M	-40.98M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	301.00K	-	-	-	0	0	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-16.83M	-28.27M	-32.01M	-46.91M	-40.19M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-6.04M	-7.42M	-8.99M	-9.68M	-11.76M	-13.25M	-13.36M	-13.98M	-9.81M	-7.58M	-5.06M	-4.78M	-5.79M	-6.93M	-6.09M	-5.48M	-6.23M	-5.84M	-7.84M	-7.27M	-14.18M	-11.99M	-20.65M	-23.55M	-18.53M	-26.42M	-23.14M	-28.98M	-33.01M	-28.36M	-27.98M	-14.94M	-78.78M	-	-	-16.83M	-28.27M	-32.01M	-46.91M	-40.19M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.07	-2.25	-1.60	-1.61	-7.64	-4.24	-3.21	-49.23	-38.63	-535.72	-1,920.85	-	-	-2.84	-3.86	-3.59	-3.98	-2.93
R&D Expense	4.08M	5.22M	-	6.83M	8.87M	10.31M	-	10.67M	7.52M	5.47M	2.99M	2.81M	3.91M	5.17M	4.07M	3.26M	3.90M	3.55M	5.05M	4.68M	10.57M	8.81M	15.33M	18.13M	13.08M	18.42M	16.58M	22.20M	26.51M	21.98M	21.05M	12.86M	9.70M	9.11M	-	7.44M	10.82M	9.29M	-	18.21M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	7.77M	10.09M	13.11M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	4.74M	7.76M	6.64M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3.03M	2.33M	6.47M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	112.09M	121.41M	77.48M	129.16M
Operating Income	-	-	-1.93M	-3.38M	-6.66M	-10.89M	-27.66M	-48.16M	-38.97M	-21.29M	-26.32M	-28.83M	-50.51M	-	-112.09M	-118.38M	-75.15M	-122.69M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-110.84M	-114.09M	-125.38M	-122.01M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.23M	89.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-110.22M	-116.66M	-130.04M	-124.02M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-202.00K	-221.00K	-1.96M	-3.47M	-9.45M	-10.88M	-27.62M	-48.05M	-38.84M	-21.12M	-26.09M	-28.62M	-50.46M	-	-110.22M	-116.66M	-130.04M	-124.02M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-65,400.00	-14,720.25	-176.60	-14.57
R&D Expense	-	-	584.30K	1.16M	2.58M	4.65M	18.62M	35.50M	28.53M	13.34M	17.56M	18.19M	36.16M	68.84M	81.88M	86.66M	39.97M	44.49M

Compounded Sales Growth

5 Years:	-
1 Year:	183.20%

Compounded Profit Growth

5 Years:	-4.17%
1 Year:	-

Stock Price Performance

1 Year:	-69.00%
6 Months:	-12.43%
3 Months:	-11.74%
1 Month:	-0.56%

Balance Sheet (Annual)

Figures in USD.

Metric	May 2007	Jun 2007	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	184.00K	425.45K	2.12M	8.74M	39.54M	47.02M	27.51M	26.75M	26.32M	14.56M	98.18M	-	225.69M	154.46M	162.89M	277.17M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	130.78M	47.77M	119.00M	228.88M
Cash & Equivalents	-	-	-	-	-	-	-	1.78M	8.20M	38.18M	19.18M	18.94M	25.50M	25.03M	11.25M	77.07M	-	120.23M	24.95M	98.78M	207.64M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	14.15M	8.41M	7.01M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3.68M	6.27M
Total Liabilities	-	-	-	-	-	359.45K	2.88M	1.16M	2.22M	3.45M	6.76M	2.15M	2.14M	2.65M	5.14M	10.54M	-	18.51M	48.93M	23.33M	32.02M
Current Liabilities	-	-	-	-	-	340.28K	925.28K	1.14M	2.21M	3.38M	6.65M	2.12M	2.13M	2.65M	5.13M	9.82M	-	18.18M	18.88M	18.31M	30.84M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.56M	4.67M	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	760.00K	9.81M	8.12M	1.31M
Total Equity	0	0	-415.00K	-545.00K	-537.00K	-175.00K	-2.45M	959.00K	6.51M	36.09M	40.26M	25.36M	24.62M	23.66M	9.42M	87.65M	-	207.18M	105.53M	139.56M	245.15M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.82K	18.32K	4.39M	12.79M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.23M	-2.64M	-5.71M	-	-	-	-37.31M	-19.13M	-23.97M	-26.68M	-48.57M	-	-98.05M	-102.00M	-60.92M	-99.84M
Investing Cash Flow	-94.37K	302	-35.76K	-	-	-	16.55M	7.17M	-6.00K	-17.00K	-8.56M	-	-48.15M	-29.07M	-120.00K	-4.53M
Financing Cash Flow	1.39M	2.61M	7.49M	-	-	-	20.50M	18.52M	23.54M	12.92M	123.11M	-	87.84M	36.52M	134.87M	214.53M
Capital Expenditure	-34.28K	-2.76K	-36.00K	-15.00K	-319.00K	-118.00K	-66.00K	-5.00K	-6.00K	-17.00K	-8.56M	-	-48.15M	-7.89M	-120.00K	-3.37M
Free Cash Flow	-1.27M	-2.64M	-5.75M	-	-	-	-37.38M	-19.13M	-23.98M	-26.70M	-57.13M	-	-146.20M	-109.90M	-61.05M	-103.21M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-58.36M	-94.56M	73.83M	110.16M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	-	-	13.96M	-	13.76M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.0%	23.1%	49.3%
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,523.9%	-744.5%	-936.1%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,501.8%	-1,288.3%	-946.2%
ROE %	37.1%	41.2%	1,122.3%	141.4%	-985.4%	-167.1%	-76.5%	-119.4%	-153.2%	-85.8%	-110.2%	-303.9%	-57.6%	-	-53.2%	-110.6%	-93.2%	-50.6%
ROCE %	-	-	1,234.1%	675.9%	-680.5%	-166.9%	-76.5%	-119.3%	-153.5%	-86.5%	-111.2%	-305.9%	-57.2%	-	-54.0%	-87.3%	-52.0%	-49.8%

Shareholding Pattern

Insiders

0.13%

Institutions

41.42%

Public Float

41.47%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	6.07%	968.18K	$11.94M
2	Vanguard Capital Management LLC	3.25%	518.65K	$6.39M
3	Citadel Advisors Llc	2.94%	468.71K	$5.78M
4	Jones Hill Capital LP	2.84%	452.12K	$5.57M
5	Geode Capital Management, LLC	1.97%	313.29K	$3.86M
6	Balyasny Asset Management LP	1.96%	313.08K	$3.86M
7	UBS Group AG	1.45%	231.68K	$2.86M
8	State Street Corporation	1.45%	230.61K	$2.84M
9	Millennium Management Llc	1.38%	219.67K	$2.71M
10	AQR Capital Management, LLC	1.01%	161.21K	$1.99M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TNXP

No recent headlines available.

TNXP · Healthcare